Adults with plaque psoriasis aged 65 years and older had similar responses to IL-17 and IL-23 inhibitors to that of younger adults.

A retrospective analysis of US medical records of people aged 65-95 years finds those with psoriasis on systemic therapies ...

Discover a study in which researchers examined three international cohorts of patients with moderate-to-severe psoriasis ...

For patients with psoriasis receiving biologic therapy, residual inflammation (RI), defined as increased inflammatory markers in blood, characterized by high-sensitivity C-reactive protein, despite ...

8% of patients maintained that the ongoing war had affected the quality of the treatment they are receiving for psoriasis.

There is no cure for psoriasis and very little has changed in psoriasis treatments over the last 50 years. Moreover, currently available treatments are often fraught with uncomfortable side-effects, ...

Certain biologic therapies, such as ustekinumab, significantly effect hematological and lipid parameters in patients with psoriasis.

Innovent Biologics doses first participant in phase 3 clinical study of picankibart: San Francisco Friday, May 30, 2025, 12:00 Hrs [IST] Innovent Biologics, Inc, a world-class bio ...

About 1 in 3 people with psoriasis who achieved clear skin with biologic drugs still had underlying inflammation that may ...

Starjemza (ustekinumab-hmny) was approved by the FDA this week as a biosimilar to Stelara. 2 A pair of clinical trials ...

THURSDAY, May 29, 2025 (HealthDay News) — Belly flab appears to be a stronger warning sign for psoriasis than fat located ...

Among 25 different measures of adiposity, abdominal fat was significantly associated with a risk for psoriasis. Among 25 ...